IL-6 Genotype

Some people seem to run hot. Their inflammation markers creep up after minor infections, their joints feel achy without a clear injury, and their cardiovascular numbers drift in the wrong direction earlier than their friends. Part of that pattern can be written into the DNA you inherited at conception, particularly in the gene for IL-6 (interleukin-6), a protein your immune system uses to coordinate inflammation throughout your body.

This test reports inherited differences (called variants) in the IL-6 gene. Those variants can nudge how much IL-6 your body produces under stress, and they have been linked, in some populations and some diseases, to differences in cancer, heart disease, diabetes, and inflammatory disease risk. The signal is real but uneven, which is why this is best understood as an exploratory marker, not a fortune-teller.

What IL-6 Does in Your Body

IL-6 is a small protein your immune cells release when they detect infection, injury, or chronic stress. It tells the liver to make acute-phase proteins like CRP (C-reactive protein), helps coordinate fever, and steers immune cells toward more aggressive responses. In short bursts, this is exactly what you want. In chronic excess, the same signal contributes to autoimmunity, atherosclerosis, and tumor-friendly inflammation.

Under normal conditions, blood IL-6 sits at very low concentrations, but during severe inflammation such as sepsis or major trauma it can rise more than a thousand-fold above baseline. The IL-6 gene contains the instructions your cells use to build this protein. Small inherited spelling changes in the gene's promoter region (the on-off switch that controls how loudly the gene gets read) can shift how much IL-6 your body makes when the immune system is triggered.

The Specific Variants This Test Reports

Most clinical and research attention has focused on three single-letter changes in the IL-6 promoter, written as rs1800795 (-174G/C), rs1800796 (-572G/C), and rs1800797 (-597G/A). Each spelling option (the G, C, or A) is an allele, and you inherit one copy from each parent.

Laboratory work shows that the proteins that switch on IL-6 production bind more tightly to the G version at position -174 than to the C version, suggesting these are functional changes rather than silent spelling differences. People homozygous for the haplotype carrying guanine at -597 and -174 produced the most IL-6 when their blood cells were challenged with a bacterial stimulus in the lab. Importantly, this functional effect appears to be cell-type specific. Studies show the -174 variant strongly influences IL-6 production in fibroblasts (connective-tissue cells) but not in monocytes (a type of white blood cell), which helps explain why disease associations are not consistent across conditions. In a Ghanaian adult population, one promoter variant explained only a small portion of the differences in blood IL-6 levels between people, meaning that genotype is one input among many.

Cancer Risk

The largest synthesis to date pooled 118 studies covering more than 50,000 cancer cases and 65,000 controls. The rs1800796 variant was modestly associated with overall cancer risk in one statistical model, with an odds ratio of about 1.12 (people carrying one C and one G were about 12% more likely to have cancer than people with two of the same letter). The effect is not large, but it was visible across the combined data.

Subtype patterns are more telling than the overall number. The rs1800795 variant was linked to cervical, liver, and prostate cancers. The rs1800796 variant was linked to lung, prostate, and stomach cancers. The rs1800797 variant was linked to cervical cancer. In a separate breast cancer meta-analysis, only rs1800797 showed a significant risk signal among seven IL-6 variants studied. The signal depends on which cancer you are asking about.

Heart Disease Risk

Cardiovascular evidence is the strongest single area for this gene, but the association is strongly population-dependent. A pooled analysis of coronary artery disease found rs1800796 carriers had meaningfully higher odds of disease across multiple genetic models. A separate acute coronary syndrome meta-analysis found a significant association for rs1800795 (-174G>C) but not for the -572G>C variant. Other meta-analyses, however, show the rs1800795 cardiovascular signal is largely driven by Asian and Asian Indian populations, while European cohorts often show no significant association. The same letter does not carry the same weight across ancestries.

Genotype can also mark prognosis once heart disease is present. In a 10-year follow-up of people with established cardiovascular disease, those with the rs1800795 CC genotype had about 72% higher risk of a combined cardiovascular event (hazard ratio 1.72), and AA carriers at rs1800797 had about 62% higher risk (hazard ratio 1.62). In a Mexican imaging study, rs1800796 was associated with thicker carotid artery walls, a sign of early atherosclerosis before any clinical event.

Type 2 Diabetes

Diabetes associations are real but population-specific. In an Ethiopian study, people with the rs1800795 GG genotype were about 4.6 times as likely to have type 2 diabetes as those with CC or GC genotypes. In a Ghanaian study, the rs1800796 GC genotype carried substantially higher odds of type 2 diabetes versus the most common genotype, with smaller but still meaningful effects for rs1800795.

The picture flips in other groups. A large meta-analysis of nearly 27,000 people found no substantial relationship between the -174G>C variant alone and obesity. A separate meta-analysis of more than 20,000 participants found no significant overall link with type 2 diabetes, though there was a borderline signal suggesting C-allele carriers had about a 9% lower risk. The same letter combination does not carry the same meaning in every ancestry.

Inflammatory and Autoimmune Disease

In a study of 335 people with asthma, those carrying the GC genotype at rs1800795 had about 5 times the odds of severe asthma. In rheumatoid arthritis patients, carriers of the -174C allele had higher cardiovascular disease prevalence even after adjusting for traditional risk factors (odds ratio 1.92), along with higher blood IL-6 levels. A meta-analysis tying IL-6 genotypes to lumbar disc disease found GG carriers at rs1800795 and rs1800797 expressed more IL-6 in spinal tissue than carriers of the other genotypes.

Infectious and Transplant Outcomes

In Malaysian adults, rs1800796 and a nearby variant were associated with protection against chronic hepatitis B and with viral clearance. A Korean study of more than 1,000 hepatitis B patients found no association between the same promoter region and disease progression, illustrating again how population matters. The COVID-19 picture is genuinely inconsistent: some cohorts link the rs1800795 C allele to higher infection risk and severity, while others link the G allele or GG genotype to worse outcomes and mortality. A reasonable summary is that the C allele has been tied more clearly to becoming infected than to dying from it, but the literature is unsettled.

In kidney transplantation, donor IL-6 CC genotype was associated with reduced graft loss, and a combined IL-6 and IL-10 genetic risk score independently predicted long-term graft failure. A separate analysis, however, linked the donor C allele to increased biopsy-proven rejection in male donors, again showing that context matters. For liver transplant rejection, genotype and allele distributions at -174 differed between rejection and non-rejection groups.

Why the Same Variant Can Point Different Directions

If you read the literature quickly, IL-6 genotype findings can look contradictory. The same letter at the same position is sometimes called a risk allele, sometimes a protective allele, depending on the disease and the population studied. This is not a paradox once you frame it correctly. IL-6 is a pleiotropic signal, meaning the same protein does many different jobs in different tissues. A genotype that mildly raises baseline IL-6 might increase chronic inflammatory disease risk while also strengthening certain infection defenses. The same variant also behaves differently in different cell types, raising IL-6 output in fibroblasts but not in monocytes, which adds another layer of context. Variants also travel together in haplotypes (linked blocks inherited as a unit) that differ between ancestries, so the effect of any single letter depends on which other letters it is sitting next to. Read this test as a phenotype indicator, not a simple good-or-bad scorecard.

When Results Can Be Misleading

Several issues specific to genetic testing can change how you should read this result.

• Variant panel coverage: this assay reports specific positions in the IL-6 gene, mainly in the promoter region. A result that does not list a rare variant does not rule it out, because the test only looks at the positions it is designed to detect.
• Ancestry-specific frequencies: the IL-6 promoter alleles occur at very different frequencies across African, Asian, and European populations, and a variant common in one group may be rare in another. The clinical meaning of a result depends on which population the supporting studies were done in.
• Single SNP versus haplotype effects: testing only one promoter variant can be misleading because the IL-6 promoter behaves as a linked block, and haplotypes often outperform single letters at predicting how much IL-6 your cells produce.
• Cell-type specific effects: the same variant can change IL-6 output in some tissues but not others, which is part of why disease associations differ across conditions.
• Clinical-grade versus direct-to-consumer reports: a consumer genetic report might list one of these positions without the lab quality or interpretation framework a clinical-grade test provides, so two reports can look like they disagree when they are really measuring different things.

A One-Time Result, Used For Life

Your IL-6 genotype is fixed at conception and does not change over time. There is no need to retest the gene itself, except in the rare case where a result was ambiguous and a confirmatory method like Sanger sequencing is warranted. The value of this test comes from integrating it into ongoing decisions about which other markers to watch, not from repeating the genetic test itself.

What does deserve serial tracking are the downstream markers that reflect what IL-6 is actually doing in your body right now. hs-CRP (a sensitive measure of background inflammation) responds to IL-6 signaling in the liver and changes with diet, exercise, infection, and disease activity, though it is also influenced by many factors beyond IL-6. If your IL-6 genotype suggests a baseline tendency toward higher inflammation, getting a baseline hs-CRP, retesting in 3 to 6 months after any lifestyle change, and then at least annually gives you the dynamic picture your fixed genotype cannot.

What to Do With an Unexpected Result

Because IL-6 genotype is a research-level marker without standardized clinical cutpoints, an unexpected finding should drive workup and stratification, not panic. The reasonable next steps depend on the pattern of findings, not on a single number.

• Pair with current inflammation status: order hs-CRP and, if relevant, fibrinogen to see whether your current biology actually reflects elevated inflammatory tone, since a high-risk genotype with quiet downstream markers behaves very differently from one with active inflammation.
• Strengthen cardiovascular workup: if your genotype carries the heart disease signal (most clearly rs1800796 and the rs1800795 CC pattern, especially in Asian or Asian Indian ancestry), tighten your lipid panel cadence, consider ApoB and Lp(a) to refine cardiovascular risk, and treat the result as a reason to act earlier on modifiable risk factors.
• Layer in metabolic markers: in the right ancestry context, IL-6 variants track with diabetes risk, so fasting insulin, HbA1c, and a sensible glucose response test give a clearer picture than genotype alone.
• Loop in the right specialist: a cardiologist, rheumatologist, or genetic counselor can interpret your genotype in the context of family history and existing diagnoses, which is where this marker becomes most useful.

Read in isolation, an IL-6 genotype rarely changes a major decision. Read alongside hs-CRP, lipid markers, and family history, it can sharpen the question of how aggressively to monitor and intervene on the systems IL-6 actually drives.